FDA
-
-
-
-
-
-
-
Perrigo Reports Second Quarter Fiscal Year 2023 Financial Results From Continuing Operations
-
-
-
-
-
-
-
PERRIGO ANNOUNCES U.S. FDA APPROVAL FOR NICOTINE COATED MINT LOZENGE
-
-
-
-
-
-
-
Perrigo Announces Chief Executive Officer Retirement and Succession Plan
-
-
-
-
-
-
-
Perrigo Launches its 3-Year Optimize and Accelerate Strategic Plan, Issues Fiscal 2023 Guidance and Introduces 2025 Financial Targets at Investor Day
-
-
-
-
-
-
-
PERRIGO ANNOUNCES JOINT FDA ADVISORY COMMITTEE TO REVIEW OPILLĀ® DAILY ORAL CONTRACEPTIVE FOR OVER-THE-COUNTER (OTC) USE
-
-
-
-
-
-
-
Perrigo's (PRGO) HRA Pharma Submits Application to FDA for First-Ever OTC Birth Control Pill
-
-
-
-
-
-
-
Perrigo Announces New Consumer Self-Care Americas (CSCA) Leadership
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

